November 08, 2021
STELLAPHARM was born to care and protect patient’s health, to help enhancing their lives and living longer. Your health, for today and for future.
The Ministry of Health has authorized the use of COVID-19 drug Molnupiravir for emergency conditions.
The Ministry said that Molnupiravir is an oral and oral anti-COVID pill that is safe and highly effective for treating COVID-19.
Molnupiravir is manufactured by Mylan Laboratories Limited, based in India.
The Ministry of Health states that the conditions for the use of this drug are used only during the public health emergency of COVID and is an alternative treatment that is under research and evaluation and used under the priority of the Royal Government, As stated in the current national medicine deployment plan and priority groups.
Source: KHMER Times
Stellapharm is one of leading generics pharmaceutical companies and strong producer of anti-viral drugs in Vietnam. The company established in Vietnam in 2000; and focuses on both prescription drugs and non-prescription especially in cardiovascular diseases, antiviral drugs, anti-diabetics drugs, etc. and our products are now used by millions of patients in more than 50 countries worldwide.
The company is globally recognized for its quality through our facilities have been audited and approved by stringent authority like EMA, PMDA, Taiwan GMP, local WHO and others.
Additional information for this article: Stellapharm J.V. Co., Ltd. – Branch 1
A: 40 Tu Do Avenue, Vietnam – Singapore Industrial Park, An Phu Ward, Thuan An City, Binh Duong Province, Vietnam
T: +84 274 376 7470 | F: +84 274 376 7469 | E: firstname.lastname@example.org | W: www.stellapharm.com
By Stephanie NolenOct. 17, 2021 Merck has taken a step to make its antiviral pill available in poor nations, but many obstacles remain for broad access to coronavirus drugs. Nearly a year after the first Covid-19 vaccination campaigns began, the vast majority of the shots have gone to people in wealthy nations, with no clear
Sept 29 (Reuters) – Laboratory studies show that Merck & Co’s (MRK.N) experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant, highly transmissible Delta, the company said on Wednesday. Since molnupiravir does not target the spike protein of the virus – the target of
Merck and Ridgeback Biotherapeutics said Friday they’ve developed a drug that reduces the risk of hospitalization or death by around 50% for patients with mild or moderate cases of Covid. The companies plan to seek emergency authorization for the antiviral Covid treatment after the medicine showed “compelling results” in clinical trials. The drug, molnupiravir, is
A novel coronavirus, originally identified in Wuhan City, China, was reported to the World Health Organization on 31 December 2019, and the associated disease has subsequently become a worldwide pandemic. An effective antiviral therapeutic has since been intensively sought. Coronaviruses use an RNA-dependent RNA polymerase (RdRp) for the replication and transcription of their RNA genome.
(CNN)_During the global scramble to secure vaccines, many countries in Asia-Pacific were slow off the mark. This time, they’re not making the same mistake.Countries around the region are rushing to place orders for the latest weapon against Covid-19: an antiviral pill that isn’t even authorized for use yet. Molnupiravir — produced by US pharmaceutical company
[Updated to July 2021] The results of the trial demonstrate the safety, tolerability, and antiviral efficacy of molnupiravir to reduce replication of SARS-CoV-2 and accelerate clearance of infectious virus and support ongoing trials of molnupiravir to prevent progression of COVID-19 and eliminate onward transmission of SARS-CoV-2. After more than one year into the coronavirus disease